BRCA1 and the DNA helicase FANCJ (also known as BACH1 or BRIP1) have common functions in breast cancer suppression and DNA repair. However, the functional significance of the direct interaction between BRCA1 and FANCJ remains unclear. Here, we have discovered that BRCA1 binding to FANCJ regulates DNA damage repair choice. Thus, when FANCJ binding to BRCA1 is ablated, the molecular mechanism chosen for the repair of damaged DNA is dramatically altered. Specifically, a FANCJ protein that cannot be phosphorylated at serine 990 or bind BRCA1 inhibits DNA repair via homologous recombination and promotes polg-dependent bypass. Furthermore, the polg-dependent bypass promoted by FANCJ requires the direct binding to the mismatch repair (MMR) protein, MLH1. Together, our findings implicate that in human cells BRCA1 binding to FANCJ is critical to regulate DNA repair choice and promote genomic stability. Moreover, unregulated FANCJ function could be associated with cancer and/or chemoresistance.
Introduction
BRCA1 function and tumor suppression depend on the BRCA1 C-terminal (BRCT) region, which contains two discrete domains called BRCT repeats. Mutations in the BRCT repeats result in defective DNA damage repair, such as failure to induce cell-cycle checkpoints and sensitivity to DNA double-stranded breaks (DSBs) and interstrand cross-links (ICLs) (Kim and Chen, 2008) . These BRCTs also mediate the direct binding of BRCA1 to the FANCJ DNA helicase (also known as FANCJ/ BRIP1) (Cantor et al., 2001) . FANCJ phosphorylation at serine 990 is required to mediate the BRCT-FANCJ interaction such that a serine to alanine mutation (S990A) ablates this interaction (Yu et al., 2003) . Similar to BRCA1, mutations in FANCJ have been associated with hereditary breast cancer (Cantor et al., 2001; Seal et al., 2006) . In addition, FANCJ is mutated in the rare childhood disease, Fanconi anemia (FA), within the FANCJ (FA-J) patient complementation group (Levitus et al., 2005; Levran et al., 2005; Litman et al., 2005) .
It has been proposed that the FA pathway maintains genomic integrity by coordinating at least two DNA repair mechanisms. One of these mechanisms is homologous recombination (HR), a typically error-free DNArepair mechanism that uses the homologous sequence in a sister chromatid for repair. HR is critical to repair DSBs, which can form when ICLs fail to be processed and replication forks collapse. Defects in HR characterize BRCA1-, FANCJ-, and BRCA2-deficient cells (Moynahan et al., 1999 (Moynahan et al., , 2001 Litman et al., 2005) . Evidence also suggests that the FA pathway promotes ICL resolution by a mechanism engaging the errorprone translesion synthesis (TLS) polymerases. Supporting this possibility, fewer TLS-like point mutations are present in the genome of FA cells (Patel and Joenje, 2007) . Moreover, the TLS polymerases REV1 and REV3 function with the FA protein FANCC to promote ICL resistance (Niedzwiedz et al., 2004) . Consequently, the FA pathway has been proposed to coordinate both TLS and HR to resolve DNA ICLs as well as other DNA lesions thereby limiting the severity of mutagenesis (Niedernhofer et al., 2005; Hinz et al., 2006; Patel and Joenje, 2007) .
Current models predict that TLS can function independent of HR. TLS is not expected to repair lesions, but facilitate lesion tolerance or bypass (Dronkert and Kanaar, 2001 ). In particular, polZ has been implicated in recombination-independent repair of ICLs generated by mitomycin C (MMC) (Zheng et al., 2003) as well as in the cellular tolerance to cisplatin (Albertella et al., 2005) . Because of the unique structure of its active site, polZ replicates through cross-linked DNA (Alt et al., 2007) . Depending on the lesion bypassed, TLS can be mutagenic or error-free. For example, polZ bypasses ultraviolet (UV) light-induced thymidine-thymidine dimers in an error-free manner and bypasses intrastrand cross-links and ICLs, once unhooked, in an error-prone manner (Zheng et al., 2003; Prakash et al., 2005) . Depending on the type and severity of DNA damage, TLS is activated by a Rad6-Rad18-dependent PCNA monoubiquitination (Kannouche and Lehmann, 2004) that loads different TLS polymerases in a lesion-specific manner (Barbour and Xiao, 2003; Papouli et al., 2005) .
Given that both FANCJ and BRCA1 are critical for HR, genomic stability, breast cancer suppression, and ICL resistance (Cantor and Andreassen, 2006) , we hypothesized that these two proteins likely function together in ICL repair. However, recent studies support independent functions. In particular, the ICL sensitivity of FANCJ-null chicken and patient cells was rescued with mutant versions of FANCJ that cannot interact with BRCA1 (Bridge et al., 2005; Peng et al., 2007) . This finding leads one to wonder what is the functional role for the BRCA1-FANCJ interaction.
Here, we identify that when uncoupled from BRCA1, FANCJ functions to inhibit HR and promote polZdependent bypass. As such, FA-J patient cells expressing the BRCA1-interaction defective mutant, FANCJ S990A resist DNA damage in a polZ-dependent manner. Furthermore, FANCJ S990A requires the MLH1 interaction to promote resistance to agents that induce ICLs. Together, our data implicate that in human cells, BRCA1 binding to FANCJ is critical to regulate DNA repair and bypass mechanisms to promote genomic stability.
Results
The DNA damage response is altered when FANCJ is uncoupled from BRCA1 In response to ICLs, FA cells undergo a prolonged G2/M accumulation that correlates with ICL sensitivity (Wang, 2007) . Restoration of the missing FA gene, such as FANCJ in FA-J patient cells, restores ICL resistance and reduces the G2/M accumulation, most likely because cells process ICLs and re-enter the cell cycle (Litman et al., 2005; Peng et al., 2007) . The finding that correction is also achieved on introduction of the BRCA1-interaction defective mutant FANCJ S990A (Peng et al., 2007) (Peng et al., 2007) (Figures 1a and c ; Supplementary Figure 1A) . Interestingly, the maximum G2/M accumulation in the FANCJ S990A complemented FA-J cells was B25%, as compared with FANCJ WT at B40% (Figure 1b) . Fewer FA-J cells accumulated at G2/M at all times when they were complemented with FANCJ S990A than when complemented with FANCJ WT or vector ( Figure 1b) . However, the growth of untreated cells was not measurably different (Supplementary Figure 1b) . 
FANCJ
S990A reduces RAD51 foci and HR Zeocin induces DSBs and sensitizes HR-defective cells (Delacote et al., 2007) . Thus, we reasoned the zeocin sensitivity of FA-J cells complemented with FANCJ (Figure 2c ). To rule out the possibility that zeocin differentially affected the FA-J cell lines and the number of cells in S-phase, in which RAD51 foci are most prominent, we measured cell-cycle distributions and found no significant differences (Supplementary Figure 3A) .
Next, we examined the consequence of expressing FANCJ mutants on DSB-induced HR. DSBs were induced by transient expression of I-Sce1 in an established U2OS cell line containing an integrated copy of the pDR-GP reporter. With this reporter, if HR occurs, GFP is expressed, which is quantifiable by flow cytometric analysis (Pierce et al., 1999 Figure 4B) . Together, these data suggested that expression of FANCJ S990A in U20S or FA-J cells reduced RAD51-based HR, but not crosslink resistance.
MMC-induced polZ foci are enhanced in U2OS cells expressing FANCJ

S990A
Given these findings, we hypothesized that resistance to agents that induce ICLs was mediated by a recombination-independent mechanism such as TLS. In particular, the TLS polymerase polZ can facilitate bypass of lesions that escape excision repair such as unhooked ICLs and UV lesions (Kannouche and Lehmann, 2004; Nojima et al., 2005) . Thus, we sought to examine whether the reduced HR in U2OS cells expressing FANCJ S990A corresponded with elevated eGFP-polZ foci that have been shown to form in response to UV (Kannouche et al., 2001) . First, we sought to confirm this UV-dependent eGFP-polZ foci formation and its dependence on Rad18 (Watanabe et al., 2004) . U2OS cells were cotransfected with eGFP-polZ and -siRNA targeting luciferase (luc) or Rad18; UV irradiated and cells positive for eGFP-polZ foci were counted. In response to UV, polZ foci clearly formed in B35% of the cells (Figure 3a) . Moreover, the number of cells with eGFP-polZ foci was reduced B4-fold when Rad18 was depleted. Next, the U2OS cells stably expressing vector, FANCJ differentially affects the number of cells in S-phase, in which polZ foci are most prominent (Kannouche et al., 2001 ), we measured cell-cycle distributions before and after UV or MMC in control or FANCJ over-expressed cells and found no significant changes (Supplementary Figure 3b) .
Cells expressing FANCJ
S990A rely on polZ for MMC resistance Given that polZ readily bypasses UV-induced thymidine-thymidine dimers as well as MMC-induced ICLs (Zheng et al., 2003; Prakash et al., 2005) , we considered that the MMC and hyper UV resistance of FA-J cells expressing FANCJ S990A (Figure 1c) (Figures 4a and b) . Consistent with this effect being due to polZ-depletion and not off-target affects, depletion of polZ with either of two distinct siRNAs was substantial B90% (Figure 4b ) and also uniquely reversed the MMC sensitivity of FA-J cells expressing FANCJ S990A ( Figure 4c ). As Rad18 is required for polZ foci formation (Figure 3a ) (Watanabe et al., 2004) , we tested how Rad18 depletion affected the MMC resistance of Figures 5B and  6 ). In contrast, Rad54-or Rev1-siRNAs did not affect the MMC resistance of the FA-J cell lines (Figure 4d) . Introduction of siRNAs into the FA-J cell lines had minimal affect on cell viability (Supplementary Figure 7) . Immunoblot analysis revealed that Rad18, Rad54, and Rev1 were depleted; however, Rad54 and Rev1 expression was lower in vector FA-J cells and only partially reduced by siRNAs (Figure 4e) . Thus, the data most clearly show that FA-J cells expressing FANCJ
S990A
, in contrast to FANCJ WT , rely on polZ-dependent bypass for ICL resistance.
To confirm the polZ dependence of our findings, we next tested whether over-expression of FANCJ S990A differentially affected the MMC or UV resistance of polZ-null or polZ-complemented XPV patient cells (Kannouche et al., 2001) . As expected, the polZcomplemented XPV cells expressed polZ and were more resistant to UV than the non-complemented XPV cells (Kannouche et al., 2001) (Supplementary Figures 8A  and B Figure 8B ). Altogether, the data strongly support that the BRCA1-interaction defective mutant, 
FANCJ
S990A promotes resistance to MMC and UV in a polZ-dependent manner.
S990A requires MLH1 binding to promote ICL resistance Previously, we identified that FANCJ WT binds directly to MLH1, and this interaction is required for MMC resistance (Peng et al., 2007) . MLH1 binds directly to the FANCJ helicase domain through lysines 141 and 142. To address whether the MLH1 interaction with FANCJ S990A was also required for MMC resistance, we replaced lysines 141 and 142 of FANCJ with alanines (A), which ablates MLH1 binding, but does not alter FANCJ helicase function (Peng et al., 2007 (Figures 5a and b) . In contrast to FANCJ (Figure 5d ), suggesting that FANCJ S990A promotes polZ-dependent TLS in a MLH1-dependent manner (Figure 5e ).
Discussion
In this study, we explore the possibility that FANCJ binding to BRCA1 is important for ICL repair in mammalian cells. This possibility was proposed based on their direct binding and common functions in breast cancer suppression, HR, and ICL repair. We provide data that support this hypothesis by demonstrating that uncoupling FANCJ from BRCA1 alters the DNA damage response. Specifically, (1) . Moreover, polZ-null XPV cells transfected with FANCJ S990A were not hyper-UV or MMC resistant unless polZ was re-introduced. Together, these data suggest that FANCJ has antirecombination and TLS functions that are normally regulated by BRCA1 binding. Moreover, we find that the BRCA1-bound or -unbound FANCJ requires its MLH1 interaction to promote ICL resistance.
FANCJ likely has a complex role in HR: contributes to HR when bound to BRCA1 and inhibits HR when unbound to BRCA1. If FANCJ functioned only as an anti-recombinase depletion of FANCJ would be expected to enhance HR. Instead, FANCJ depletion reduces HR, similar to BRCA1 depletion (Litman et al., 2005) . Further indicating a positive role for FANCJ in HR, in response to DSBs induced by zeocin complementation of FANCJ WT in FA-J cells enhanced the appearance of DNA damage induced RAD51 foci (Figures 2a and c) . Whether the role of FANCJ in HR is BRCA1 regulates FANCJ DNA repair function J Xie et al direct is not clear. Conceivably, FANCJ could have an indirect role in HR as a 'place-holder' to prevent other proteins from disrupting HR, such as the anti-recombination helicases BLM or RTEL (Bugreev et al., 2007; Barber et al., 2008) . Also consistent with a positive role in HR following ICLs, FANCJ deficiency enhanced recombination-independent repair (Shen et al., 2009) . Intriguingly, polZ also functions in HR to extend Dloop recombination intermediates (Kawamoto et al., 2005; McIlwraith et al., 2005) . These dual functions in HR and TLS are likely regulated by the DNA damage response. Similar to polZ, UV damage could link FANCJ to TLS. Here, the anti-recombination activity of FANCJ could be unleashed through loss of BRCA1 binding and gained helicase activity. This unleashed FANCJ activity could explain why BRCA1-deficient cells are defective in RAD51 foci formation and HR (Moynahan et al., 1999; Bhattacharyya et al., 2000) .
Conceivably, the anti-recombination activity of FANCJ S990A could indirectly enhance TLS. For example, the yeast helicase Srs2 promotes TLS by binding PCNA and antagonizing HR and recombination bypass pathways. The ability of Srs2 to disrupt recombination and displace Rad51 requires its enzyme activity (Barbour and Xiao, 2003; Papouli et al., 2005) . Similar to Srs2, FANCJ colocalizes at sites of replication arrest with PCNA and has been shown to translocate DNA, unwind D-loops and displace RAD51 (Gupta et al., 2005; Dupaigne et al., 2008; Sommers et al., 2009 ). Moreover, UvrD, which is structurally and functionally related to Srs2, binds the MLH1 homologue, MutL (Mechanic et al., 2000) . MutL helps to load and activate the UvrD helicase. Perhaps, MLH1 helps to load or activate the FANCJ helicase to promote TLS or HR.
FANCJ could enhance TLS not only by limiting recombination, but also by potentiating TLS. For example, FANCJ could limit negative regulators of TLS, such as mismatch repair (MMR), which detect mismatches generated by mutagenic TLS processing. Mismatch-induced MMR checkpoint signaling could generate the MMC sensitivity in FA-J cells lacking the FANCJ/MLH1 interaction. Alternatively, FANCJ S990A could directly enhance TLS by altering the structure of the stalled DNA replication fork. Failure to separate DNA strands or create a DNA loop at the ICL is thought to block NER-dependent incisions required for recombination-independent repair (Zheng et al., 2003) . The unleashed FANCJ S990A could enhance DNA strand separation in a manner distinct from the BRCA1-bound FANCJ to facilitate NER-dependent processing events and recombination-independent repair. Either scenario could explain how FANCJ S990A promotes TLS without directly binding polZ (data not shown).
Together, these findings imply that reduction or loss of BRCA1 binding to FANCJ could enable cells to survive toxic chemotherapies and provide a possible route to chemoresistance. If true, targeting FANCJ or polZ bypass could reverse resistance to agents that induce ICLs in such cancers. Likewise, a possible route to cancer in BRCA1-mutation carriers could result from excess unbound FANCJ and mutagenic bypass.
Perhaps, this is why FANCJ amplification is also linked to malignancy (Sinclair et al., 2003; Eelen et al., 2008) . In fact, loss of BRCA1 binding to FANCJ could evolve from mutations in either gene, or from loss of DNAdamage signaling components that regulate the association of these two proteins. Future studies are needed to clarify the signaling pathways that participate in regulating the switch between BRCA1-bound and -unbound FANCJ.
Materials and methods
Cell culture MCF7, U2OS, HeLa, XP30RO (XP-V)-PCDNA vector, and PCNDA-polZ complemented (generous gift of Alan Lehmann) (Kannouche et al., 2001 ) cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics. Stable cells were selected with 20 mg/ml G418. FA-J (EUFA30-F) fibroblasts were cultured in DMEM supplemented with 15% fetal bovine serum and antibiotics. FA-J cells were infected with pOZ vectors and selected as before (Peng et al., 2007) .
Cell growth and G2/M accumulation assays FA-J cells infected with pOZ (Peng et al., 2007) vectors and U2OS cells were transfected with siRNA using Fugene or Lipofectamine. siRNA reagents for polZ (siRNA PolZ pool, antisense sequence of #1, AACCCUUCAAUGUAA GUGCUU, or antisense sequence of #2, UAGUUCCUGGG CUAAUUGCUU), Rev1 (siRNA Rev1 pool), Rad18 (siRNA Rad18 pool, antisense sequence of #1, UACCAGUUCAUC UAAUAUGUU, antisense sequence of #2, AAAUUAUCC AUUAACCUGCUU, antisense sequence of #3, UUACUG AGGUCAUAUUAUCUU, or antisense sequence of #4, UGACUCUAAAGCAAACUGCUU), Rad54 (siRNA Rad54 pool), and luciferase (Luc) were obtained from Dharmacon (Lafayette, CO, USA). The FANCJ siRNA reagent was described earlier (Litman et al., 2005) . U2OS cells were infected with shRNA against pGIPZ non-silencing control, Rad18 #1 (mature antisense sequence, AAATA TATCCATGTGAGCT), or Rad18 #2 (mature antisense sequence, TTGGTCTTTGCAGCAGGGC). shRNAs were obtained from the UMMS shRNA core facility. Infected cells or XPV complemented with vector or polZ were subsequently transfected with V, FANCJ WT , or FANCJ S990A . After transfection (24-48 h), 1500-3000 U2OS cells/well or 12 500 complemented FA-J cells/well were seeded into six-well plates, respectively. Complemented FA-J cells were seeded into six-well plates at 8000 cells/well. Seeded cells were incubated overnight and left untreated or treated with MMC (Sigma, St Louis, MO, USA) for 1 h, UV (Stratalinker, Spectronics Corporation, Westbury, NY, USA), cisplatin (Sigma) for 4 h, zeocin (Invitrogen, Carlsbad, CA, USA) for 1 h, 6-TG (Sigma) for 24 h, or MMS (Sigma) for 1 h. Cells were counted after 5-8 days using a hemocytometer. Percent growth was calculated as (treated cells/untreated cells) Â 100. G2/M accumulation was assayed as described (Litman et al., 2005) , but at 0.25 mg/ml melphalan.
Antibodies for western blot analysis included BRCA1 (ms110) and FANCJ monoclonal (2G7 and 2C10) (Cantor et al., 2001) or polyclonal E67 (Cantor et al., 2004) . In addition, b-actin (Sigma), Rad18 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Rev1 (H-300, Santa Cruz), polZ (Abcam, Cambridge, MA, USA), and Rad54 (Abcam) Abs were used. , and FANCJ S990A pCDNA-3myc-6xhis and pOZ vectors have been described earlier (Cantor et al., 2001; Peng et al., 2007) . The eGFP-polZ construct was described earlier (Kannouche et al., 2001) . The FANCJ K141/142AS990A pOZ vector was generated with the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using our published primers (Cantor et al., 2001; Peng et al., 2007) .
DNA constructs
Immunofluorescence FA-J cells were either left untreated or treated with 12.5 mg/ml zeocin and incubated 12 h and processed for immunofluorescence as described (Cantor et al., 2001) . Antibodies included RAD51 (Santa Cruz 1:200) and g-H2AX (Upstate 1:500, Upstate, Temecula, CA, USA). Visualization of eGFPpolZ foci was as described (Kannouche et al., 2001) . In brief, U2OS cells were transfected with eGFP-polZ, incubated for overnight, seeded on cover slips, incubated overnight, and examined 4 h post-UV or for 24 and 48 h post-MMC. Foci counting experiments were conducted blind to the counter and in triplicate as the number of cells with 10 or more foci.
Homologous recombination U2OS pDR-GFP cells were obtained from Maria Jasin (Pierce et al., 1999) 
